Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma - Concepedia

Concepedia

Publication | Open Access

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

DOI Full Paper Access

85

Citations

25

References

2021

Year

Yousef Zakharia, Robert R. McWilliams, Olivier Rixe, Joseph J. Drabick, Montaser Shaheen, Kenneth F. Grossmann, Ravindra Kolhe, Rafał Pacholczyk, Ramses Sadek, Lucinda Tennant,

Journal for ImmunoTherapy of Cancer

Abstract

In this study, the combination of indoximod and (P) was well tolerated and showed antitumor efficacy that is worth further evaluation in selected patients with advanced melanoma.

References

	Year	Citations

Page 1